

MR. DAVID C CRON (Orcid ID : 0000-0002-9488-6847)

MR. MICHAEL N TERJIMANIAN (Orcid ID : 0000-0002-7199-807X)

DR. KENNETH J WOODSIDE (Orcid ID : 0000-0002-7495-3758)

Article type : Original Article

**Using Analytic Morphomics to Describe Body Composition Associated
with Post-Kidney Transplantation Diabetes Mellitus**

David C. Cron, BS^{1,2}; Kelly A. Noon, BS³; Devan R. Cote, BS³; Michael N. Terjimanian, MS^{1,2};
Joshua J. Augustine, MD⁴; Stewart C. Wang, MD, PhD^{1,2}; Michael J. Englesbe, MD^{1,2};
Kenneth J. Woodside, MD¹

¹Department of Surgery, University of Michigan Medical School, Ann Arbor, MI

²Morphomic Analysis Group, University of Michigan Medical School, Ann Arbor, MI

³Department of Surgery, Case Western Reserve University and
University Hospitals Case Medical Center, Cleveland, OH

⁴Department of Internal Medicine, Case Western Reserve University and
University Hospitals Case Medical Center, Cleveland, OH

Corresponding Author: Kenneth J. Woodside, MD

This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the [Version of Record](#). Please cite this article as [doi: 10.1111/ctr.13040](https://doi.org/10.1111/ctr.13040)

This article is protected by copyright. All rights reserved

Associate Professor of Surgery
Section of Transplant Surgery
Department of Surgery
University of Michigan Health System
1500 E. Medical Center Drive
Ann Arbor, MI 48109-5296
734-936-8363
734-763-3187 (fax)
woodside@umich.edu

Running Title: Morphomics, Body Composition, Diabetes

Disclosures: SCW and MJE are equity stakeholders in Prehab Technologies, LLC.

Funding: None

Abstract

Background: Better risk assessment tools are needed to predict post-transplantation diabetes mellitus (PTDM). Using analytic morphomic measurements from computed tomography (CT) scans, we aimed to identify specific measures of body composition associated with PTDM.

Methods: We retrospectively reviewed 99 non-diabetic kidney transplant recipients who received pre-transplant CT scans at a single institution between 1/2005 and 5/2014. Analytic morphomic techniques were used to measure abdominal adiposity, abdominal size, and psoas muscle area and density, standardized by gender. We measured the associations of these morphomic factors with PTDM.

Results: One-year incidence of PTDM was 18%. The morphomic factors significantly associated with PTDM included visceral fat area (OR=1.84 per standard deviation increase, $p=0.020$), body depth (OR=1.79, $p=0.035$), and total body area (OR=1.67, $p=0.049$). Clinical factors significantly associated with PTDM included African American race (OR=3.01, $p=0.044$),

hypertension (OR=2.97, p=0.041), and dialysis vintage (OR=1.24 per year on dialysis, p=0.048). Body mass index was not associated with PTDM (OR=1.05, p=0.188). On multivariate modeling, visceral fat area was an independent predictor of PTDM (OR=1.91, p=0.035).

Conclusions: Analytic morphomics can identify pre-transplant measurements of body composition that are predictive of PTDM in kidney transplant recipients. Pre-transplant imaging contains a wealth of data that may inform PTDM prevention strategies.

Key Words: analytic morphomics, obesity, body composition, kidney transplant, diabetes, new-onset diabetes after transplant, post-transplant diabetes mellitus

Introduction

Metabolic and cardiovascular complications are common following kidney transplantation, and are a significant cause of post-transplant morbidity. Post-transplantation diabetes mellitus (PTDM, sometimes termed new-onset diabetes mellitus after transplantation) is common, and affects 10-15% of kidney transplant recipients.¹⁻⁵ This complication is associated with worse post-transplant outcome, including diabetic complications, cardiovascular complications, and lower graft and patient survival.⁶⁻⁸ PTDM development is attributed in part to post-transplant immunosuppressant therapy. Namely, corticosteroids and tacrolimus can impair insulin sensitivity.³⁻⁵ However, patient-specific factors such as age, race, and hepatitis C viral infection are associated with the development of PTDM as well.^{4,5} Higher body mass index (BMI) is also associated with PTDM.^{5,9} Measurements of body composition represent important patient-specific modifiable risk factors; however, BMI fails to discriminate between fat and muscle, and thus provides an incomplete measure of body composition. More specific measurements of central adiposity, visceral and subcutaneous adiposity, and lean muscle mass may help identify PTDM risk factors and facilitate intervention.

Computed tomography (CT) scans can be used to delineate visceral adiposity from subcutaneous adiposity. Visceral adiposity is believed to be the more metabolically active fat and has been shown to be associated with insulin resistance.¹⁰ Analytic morphomics is a novel technology that uses semi-automated processing of CT scans to obtain granular measurements of body composition.^{11,12} This technology has been shown to predict surgical risk in myriad patient populations.^{11,13,14} Such CT-based methods have also been shown to identify markers of chronic

disease such as cirrhosis and diabetes.^{15,16} Recently, our group has shown that analytic morphomics can identify specific body composition associated with PTDM following liver transplantation.¹⁷ The value of analytic morphomics in kidney transplantation is unclear. This technology may be able to address the need for better pre-kidney transplant assessment of PTDM risk.

To this end, we used analytic morphomic techniques to measure pre-transplant abdominal adiposity, body size, and trunk musculature, and we correlated these measurements with incidence of PTDM in kidney transplant recipients. We aimed to identify specific body composition risk factors for PTDM. We hypothesized that greater abdominal adiposity, larger abdominal size, and lower lean muscle mass are associated with higher incidence of PTDM.

Methods

Study population

This study was reviewed and approved by the Institutional Review Boards of both the University Hospitals Case Medical Center (UHCMC, IRB#07-13-31) and the University of Michigan Medical School (UMMS, IRB#HUM00041441), and is adherent to the Declaration of Helsinki. This study was a retrospective analysis of patients who underwent kidney transplantation at UHCMC between January 2005 and May 2014 who had a CT scan in the year prior to transplant. At UHCMC, abdominopelvic or pelvic CT scans were ordered annually per clinical protocol for kidney transplant candidates who met any one of the following criteria: age ≥ 50 years, diabetes, significant cardiovascular risk, or previous transplant. These scans were obtained to assess for iliac artery calcification and operative anastomotic targets. We also included CT scans ordered for other clinical reasons, as long as the scans were within one year prior to the transplant. In patients with multiple pre-transplant CT scans, we selected the scan closest to transplant. Protocol scans were non-contrast. We excluded patients who had clinically recognized pre-transplant diabetes or received a simultaneous pancreas or liver transplant.

Typical immediate peri-kidney transplant immunosuppression regimens at UHCMC included thymoglobulin, mycophenolate mofetil, tacrolimus, and 4 days of methylprednisolone. Tacrolimus was occasionally switched to cyclosporine in the setting of tacrolimus-related toxicity. Tacrolimus target levels were 8-12 ng/ml in first 90 days and 5-8 ng/ml thereafter. All

patients typically received methylprednisolone for four days post-transplant. As part of a steroid avoidance protocol, steroids were then typically stopped or tapered, unless the patient was immunologically higher risk, had delayed graft function beyond the intravenous steroid course, or had pre-existing need for steroids, such as certain autoimmune diseases. For patients who were maintained on steroids post-transplant, prednisone maintenance dosing was typically 5mg, and sometimes as low as 2.5mg.

Clinical Data

Clinical data were retrospectively collected from the electronic medical record at UHCMC. Data were de-identified and coded and sent to UMMS to be merged with the de-identified and coded morphomic data. Clinical variables collected included age, sex, race, body mass index, end-stage renal disease etiology (hypertension, autoimmune, or other), hepatitis C viral infection, dialysis pre-transplant (including time on dialysis), prior kidney transplant, deceased donor, prednisone post-transplant, and tacrolimus or cyclosporine usage post-transplant.

Outcome: Post-transplant Diabetes Mellitus (PTDM)

All patients had at least one year of post-transplant data. Our outcome of interest was a binary measure indicating one-year PTDM incidence. PTDM was retrospectively queried from the electronic medical record at UHCMC and was defined as peak fasting plasma glucose ≥ 126 mg/dl or HbA1c $\geq 6.5\%$. We ensured that the PTDM persisted until one year post-transplant or patient death to exclude transient hyperglycemia.

Analytic morphomics

CT scans were deidentified and assigned unique identifiers before undergoing morphomic analysis by the University of Michigan Morphomic Analysis Group. Figure 1 shows the morphomic measures considered in this analysis: visceral fat area, subcutaneous fat area, subcutaneous fat anterior thickness, total body area, total body circumference, body depth (anterior-posterior axis), body width (lateral axis), total psoas area, and average psoas density. CT scans were processed using semi-automated methods programmed into MATLAB v. 2013a (MathWorks, Natick, MA). Scans were processed by research students and full-time research

associates, all of whom received extensive training. All scans were reviewed and approved by a single reviewer for quality control. The methodology for measurement of total psoas areas has been previously described.¹¹ Briefly, scans were first indexed by vertebral level to enable precise measurements. All measurements for this study were taken at the L4 vertebral level. This level is most commonly used in morphomics studies, as the psoas muscle is most reliably measured at this level. Additionally, many of the scans in this study were pelvic (to assess iliac vessels) and thus did not contain levels superior to L4. Total psoas area was the sum of the left and right cross-sectional areas taken just inferior to the L4 vertebral level. Average psoas density was computed by measuring the Hounsfield units of each individual pixel and averaging these values across all pixels in bilateral psoas muscle cross-sectional slices.¹⁸ Larger values of Hounsfield units indicate more dense muscles (i.e. less fatty infiltration).

Fat areas and body size measurements were also measured at the L4 vertebral level. Methods for computing these measurements are also well described elsewhere.^{17,18} The fascial and skin envelopes were outlined. Measurements of body depth, width, circumference, and area were made relative to the skin envelope. The Hounsfield units of each pixel within the fascial envelope were calculated, and any pixels with density within the range of fat was deemed visceral fat. Similarly, Hounsfield units of pixels between the fascial and skin envelopes were used to determine subcutaneous fat.

Statistical Analysis

Continuous variables were summarized by mean and standard deviation (SD), or median and interquartile range (IQR) if skewed. Continuous variables were compared using a Student's t-test or a Wilcoxon rank-sum test, as appropriate. Pairwise correlations were assessed using Pearson's correlation coefficient (r). Categorical variables were summarized by frequency tables and compared using Fisher's exact test. For regression analysis, morphomic variables were standardized by sex to account for variation in body size by sex. Univariate and multivariate logistic regression was used to assess the relationship of clinical and morphomic factors to PTDM, with results expressed as odds ratios (OR) with 95% confidence intervals (CI). For multivariate analysis, variables with a univariate $p \leq 0.05$ were included, and BMI was included regardless of statistical significance. Due to collinearity between different morphomic factors, we ran a separate multivariate model for each statistically significant morphomic predictor

identified on univariate analysis. For graphical display, we dichotomized BMI, with BMI ≥ 30 considered *high* BMI, which corresponded to 33% of the cohort. We also dichotomized visceral fat area, subcutaneous fat area, and total psoas area, with values in the upper tertile (gender-specific) for each measure considered *high*, and values in the lower and middle tertile considered *low*. We chose to dichotomize these measures because sample size and the binary outcome limited number of groups that could be used for categorization, and we were interested in comparing the upper extremes of body size. All significance tests were two-sided, with significance accepted at $p < 0.05$. All statistical analyses were performed using Stata v13.1 (StataCorp LP, College Station, Texas).

Results

A total of 99 patients met inclusion criteria. The median time from CT scan to transplant was 162 days (IQR 89-246). Table 1 shows demographic and clinical characteristics for the study cohort. The cohort was 65% male with a mean age of 52.9 ± 13.5 , with 25.3% of the patients African American. The mean age was 52.9 ± 13.5 years, while the median dialysis vintage (years of dialysis pre-transplant) was 1.5 years (IQR 0-4.2). 13 patients (13%) had a history of prior kidney transplant. In this cohort, 62% of patients continued prednisone post-transplant beyond the protocolled time point of postoperative day 4, and 7% of patients received cyclosporine post-transplant. Morphomic measurements in the sample were all approximately normally distributed.

We assessed correlations between the gender-standardized morphomic measures and BMI. BMI was positively correlated with all morphomic measures of fat, muscle, and body size: visceral fat area ($r=0.40$), subcutaneous fat area ($r=0.65$), subcutaneous fat anterior thickness ($r=0.64$), total body area ($r=0.68$), total body circumference ($r=0.68$), body depth ($r=0.64$), body width ($r=0.64$). BMI was weakly correlated with muscle measurements: total psoas area ($r=0.24$), average psoas density ($r=0.16$, though not significant, $p=0.121$). The correlation between visceral fat area and subcutaneous fat area was $r=0.59$. Psoas area was weakly correlated with subcutaneous fat area ($r=0.22$), and was not significantly correlated with visceral fat area ($r=0.05$, $p=0.635$).

The incidence of PTDM was 18% at one year post-transplant. Median time from transplant to PTDM diagnosis was 223 days (IQR 58-329). Of the 18 patients who developed

PTDM, 13 gained weight by 1-year post-transplant, and average weight and BMI change of those 18 patients by 1-year post-transplant was 6.9 ± 12.5 kg and 2.3 ± 4.3 , respectively. Regarding management of PTDM in these patients, 5 (27%) were managed with insulin, 6 (33%) with oral medication, and 7 (39%) were initially diet-controlled. HbA1c levels at 1 year post-transplant (within 3 months of this date) were available for 9 (50%) of the patients who developed PTDM and were on average 6.9 ± 1.5 . Table 2 shows clinical factors associated with PTDM. Three factors were significantly associated with PTDM: African American race (OR=3.01, 95% CI 1.03-8.80, $p=0.044$), hypertension (OR=2.97, 95% CI 1.04-8.44, $p=0.041$), and dialysis vintage (OR=1.24 per year on dialysis, 95% CI 1.00-1.54, $p=0.048$). BMI was not significantly associated with PTDM (OR=1.05, 95% CI 0.98-1.13, $p=0.188$). Other notable factors that were not significantly associated with PTDM included hepatitis C viral infection ($p=0.466$) and continued prednisone use post-transplant ($p=0.311$).

The morphomic factors associated with PTDM are also shown in Table 2. The following variables were significantly associated with PTDM: visceral fat area (OR=1.84 per SD increase, 95% CI 1.10-3.09, $p=0.020$), body depth (OR=1.79 per SD increase, 95% CI 1.04-3.09, $p=0.035$), and total body area (OR=1.67 per SD increase, 95% CI 1.00-2.77, $p=0.049$). Morphomic factors that trended toward significance included subcutaneous fat area ($p=0.086$), subcutaneous fat anterior thickness ($p=0.065$), and total body circumference ($p=0.075$). Of note, neither total psoas area, nor average psoas density, were associated with PTDM ($p=0.113$ and $p=0.700$, respectively).

The morphomic measurements compared between patients with and without incident PTDM are shown in Table 3. Without accounting for gender, patients who developed PTDM had 35% greater visceral fat area ($p=0.047$). There was a trend toward greater body depth in patients who developed PTDM (9% greater, $p=0.057$). Among patients with PTDM, there was no difference in morphomic measurements in insulin-controlled vs. oral medication or diet controlled patients. Figure 2 shows unadjusted rates of PTDM incidence by high and low visceral fat, subcutaneous fat, total psoas area, and BMI. Rates of PTDM were 2.6-fold higher in patients with high visceral fat area compared to low (31% vs. 12%, $p=0.027$). PTDM rates were not significantly different in patients with high vs. low subcutaneous fat area (19% vs. 18%, $p=1.000$), psoas area (22% vs. 16%, $p=0.581$), or BMI (21% vs. 17%, $p=0.590$).

For multivariate analysis, one model was run for each of the three morphomic factors identified as statistically significant on univariate analysis (visceral fat area, total body area, body depth). Due to collinearity between morphomic factors, we chose *a priori* to analyze each of these three morphomic factors in three separate multivariate models. Each model adjusted for BMI, hypertension, African American race, and dialysis vintage. The results of these models are shown in Table 4. Visceral fat area was an independent predictor of PTDM (OR=1.91 per standard deviation increase, 95% CI 1.05-3.48, p=0.035). Neither total body area (OR=1.76, 95% CI 0.87-3.56, p=0.115) nor body depth (OR=1.84, 95% CI 0.92-3.67, p=0.086) were statistically significant predictors of PTDM on multivariate analysis. No other clinical factors were statistically significantly associated with PTDM on multivariate analysis.

Discussion

With this work, we explored the utility of analytic morphomics in identifying body composition associated with PTDM in kidney transplant recipients. The prevalence of PTDM in this study was 18% at one-year post-transplant. We identified multiple specific measures of body fat and body size that were significantly associated with PTDM, including visceral fat area, total body area, and body depth. In a multivariate model adjusting for clinical factors, visceral fat area alone remained independently and significantly associated with PTDM. Interestingly, BMI was not significantly associated with PTDM in this cohort. The correlations between the morphomic measures and BMI were variable; measures of body size (total body area, body circumference, and body depth) were most strongly correlated with BMI. Pre-transplant imaging contains a wealth of patient-specific health markers that can be used for risk assessment. These findings suggest that analytic morphomics can be used to identify granular measurements of body composition that are predictive of PTDM.

Although BMI is well-established as a predictor of PTDM, its flaws are known. BMI does not account for regional fat distribution or amount of lean muscle mass—factors that are known to determine metabolic risk. Central adiposity is known to be metabolically more active and higher risk compared to peripheral adiposity.¹⁹⁻²¹ Specifically, abdominal visceral fat is believed to be more strongly associated with insulin resistance and diabetes compared to

abdominal subcutaneous fat.^{10,21} Additionally, lower lean muscle mass has been associated with insulin resistance.²² Analytic morphomic analysis of abdominal CT scans can discriminate regional fat distribution and lean muscle mass, and this this technology may provide a useful risk assessment tool in kidney transplant recipients

This study highlights the potential utility of pre-transplant CT scans for PTDM risk assessment. Our previous work in liver transplantation identified subcutaneous fat thickness as the only significant predictor of PTDM.¹⁷ This current study suggests that analytic morphomics may have more utility in predicting PTDM in kidney transplant recipients than liver recipients. Other studies have shown specific body composition correlates of PTDM, though few have used pre-transplant measures to predict incidence of PTDM. One cross-sectional study found higher visceral fat in PTDM patients (measured post-transplant) compared to controls.²³ Another study found that PTDM patients had greater waist circumference compared to controls (also measured post-transplant).²⁴ Interestingly, BMI is known to be a predictor of PTDM^{5,9} but was not a significant predictor in our sample. This is not to suggest that BMI does not predict PTDM, as sample size may have contributed to this. Rather, as morphomic measures are more specific than the composite measurement of BMI, our results suggest that morphomic measurements may be more predictive than BMI. Additionally, other previously established PTDM risk factors such as steroid use and hepatitis C were not predictive of PTDM in this study, and this finding likely reflects the study cohort characteristics (e.g. steroid avoidance protocol) and sample size limitations. Our study adds to this literature by showing that specific pre-transplant measures of fat area and body size are predictive of PTDM incidence.

CT scans are frequently ordered prior to kidney transplantation, yet the full potential of these scans is not being utilized. Beyond operative planning, CT scans can be used to identify high risk surgical candidates^{11,13}, and we suggest they also can be used to predict metabolic outcomes such as PTDM. In the context of PTDM, stronger methods of risk assessment are needed in order to identify high-risk patients who can benefit from intervention. For example, assessing specific fat and muscle measurements in kidney transplant candidates may facilitate development of nutrition and exercise interventions that are tailored to the patient's specific needs. We have had success with similar preoperative optimization programs in general surgery patients at our institution.^{25,26} Further, immunosuppression regimens can be tailored according to the patient's PTDM risk, but such clinical decisions require precise risk assessment to optimally

balance metabolic and immunologic risk. Given the results of this pilot study, we hypothesize that analytic morphomics may be able to improve risk assessment by incorporating specific measures of body composition into predictive models. Analytic morphomics has been shown to improve the discriminative ability of predictive models in other contexts.^{12,15} As a follow-up to this initial work, we plan to expand our database to multiple institutions. With a larger sample size, our future work will aim to develop robust multivariate models incorporating morphomics for prediction of PTDM.

This study has limitations. This is a single-center study, and thus the results may not be generalizable across other centers—which may partially account for differences from previously published studies from other centers. As a retrospective study, we were limited in the data we were able to collect. In particular, family history of diabetes was not reliably recorded, and consistent intervals between patients for tacrolimus dosages and levels were not available, since the patients were not in a prospective protocol. As tacrolimus has been associated with PTDM, this lack of reliable data limits ascribing PTDM etiology. Prospective collection of additional pre-transplant metabolic data would better enable us to account for baseline metabolic risk. Our sample size was a limitation, and future studies with larger sample size would enable robust multivariate predictive modeling. However, the results of this pilot study will guide our future work as we aim to identify the independent predictive utility of analytic morphomics in the context of PTDM. Lastly, these methods are applicable only to patients who receive pre-transplant CT scans. In our sample, CT scans were ordered for operative planning in patients who were older than 50, had significant cardiovascular risk, or had other clinical indications warranting imaging. This analyzed population is biased toward older and sicker patients; these findings may not be generalizable to all populations.

In conclusion, we demonstrated that analytic morphomics can identify specific pre-transplant measurements of body composition that are predictive of PTDM incidence in kidney transplant recipients. The results of this study may serve as a proof-of-concept, suggesting utility of analytic morphomics for predicting PTDM risk in kidney transplant recipients. Morphomic analysis may add to a robust assessment of PTDM risk. Such PTDM risk assessment may help mitigate PTDM by not only targeting pre-transplant risk factors, but also through tailoring immunosuppressive and other post-transplant medications, lifestyle interventions, and nutritional

support. Additional work is ongoing to expand upon these results and further explore the predictive ability and clinical utility of this novel technology.

Author contributions

DCC: conception and design, acquisition of data, analysis and interpretation of data

KAN: conception and design, acquisition of data

DRC: conception and design, acquisition of data

MNT: conception and design, interpretation of data

JJA: conception and design, acquisition of data, interpretation of data

SCW: conception and design, acquisition of data, interpretation of data

MJE: conception and design, acquisition of data, interpretation of data

KJW: conception and design, acquisition of data, interpretation of data

All authors aided in drafting or critically revising the article and approved the final manuscript.

References

1. Sharif A, Hecking M, de Vries AP, et al. Proceedings from an international consensus meeting on posttransplantation diabetes mellitus: recommendations and future directions. *Am J Transplant*. 2014;14(9): 1992-2000.
2. Porrini E, Moreno JM, Osuna A, et al. Prediabetes in patients receiving tacrolimus in the first year after kidney transplantation: a prospective and multicenter study. *Transplantation*. 2008;85(8): 1133-1138.
3. Luan FL, Steffick DE, Ojo AO. New-onset diabetes mellitus in kidney transplant recipients discharged on steroid-free immunosuppression. *Transplantation*. 2011;91(3): 334-341.
4. Montori VM, Basu A, Erwin PJ, Velosa JA, Gabriel SE, Kudva YC. Posttransplantation diabetes: a systematic review of the literature. *Diabetes Care*. 2002;25(3): 583-592.
5. Shah T, Kasravi A, Huang E, et al. Risk factors for development of new-onset diabetes mellitus after kidney transplantation. *Transplantation*. 2006;82(12): 1673-1676.

6. Burroughs TE, Swindle J, Takemoto S, et al. Diabetic complications associated with new-onset diabetes mellitus in renal transplant recipients. *Transplantation*. 2007;83(8): 1027-1034.
7. Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ. Diabetes mellitus after kidney transplantation in the United States. *Am J Transplant*. 2003;3(2): 178-185.
8. Lentine KL, Brennan DC, Schnitzler MA. Incidence and predictors of myocardial infarction after kidney transplantation. *J Am Soc Nephrol*. 2005;16(2): 496-506.
9. Lafranca JA, JN IJ, Betjes MG, Dor FJ. Body mass index and outcome in renal transplant recipients: a systematic review and meta-analysis. *BMC Med*. 2015;13: 111.
10. Hayashi T, Boyko EJ, McNeely MJ, Leonetti DL, Kahn SE, Fujimoto WY. Visceral adiposity, not abdominal subcutaneous fat area, is associated with an increase in future insulin resistance in Japanese Americans. *Diabetes*. 2008;57(5): 1269-1275.
11. Englesbe MJ, Lee JS, He K, et al. Analytic Morphomics, Core Muscle Size, and Surgical Outcomes. *Ann Surg*. 2012;256(2): 255-261.
12. Zhang P, Parenteau C, Wang L, et al. Prediction of thoracic injury severity in frontal impacts by selected anatomical morphomic variables through model-averaged logistic regression approach. *Accid Anal Prev*. 2013;60: 172-180.
13. Englesbe MJ, Patel SP, He K, et al. Sarcopenia and Mortality after Liver Transplantation. *J Am Coll Surg*. 2010;211(2): 271-278.
14. Lee JS, He K, Harbaugh CM, et al. Frailty, core muscle size, and mortality in patients undergoing open abdominal aortic aneurysm repair. *J Vasc Surg*. 2011;53(4): 912-917.
15. Krishnamurthy V, Zhang P, Ethiraj S, et al. Use of analytic morphomics of liver, spleen, and body composition to identify patients at risk for cirrhosis. *Clin Gastroenterol Hepatol*. 2015;13(2): 360-368 e365.
16. Smith SR, Lovejoy JC, Greenway F, et al. Contributions of total body fat, abdominal subcutaneous adipose tissue compartments, and visceral adipose tissue to the metabolic complications of obesity. *Metabolism*. 2001;50(4): 425-435.
17. Vaughn V, Cron DC, Terjimanian MN, et al. Analytic Morphomics Identifies Predictors of New-Onset Diabetes after Liver Transplantation. *Clin Transplant*. 2015;29(5):458-464.

18. Zhang P, Peterson M, Su GL, Wang SC. Visceral adiposity is negatively associated with bone density and muscle attenuation. *Am J Clin Nutr.* 2015;101(2): 337-343.
19. Kannel WB, Cupples LA, Ramaswami R, Stokes J, 3rd, Kreger BE, Higgins M. Regional obesity and risk of cardiovascular disease; the Framingham Study. *J Clin Epidemiol.* 1991;44(2): 183-190.
20. Misra A, Vikram NK. Clinical and pathophysiological consequences of abdominal adiposity and abdominal adipose tissue depots. *Nutrition.* 2003;19(5): 457-466.
21. Bray GA, Jablonski KA, Fujimoto WY, et al. Relation of central adiposity and body mass index to the development of diabetes in the Diabetes Prevention Program. *Am J Clin Nutr.* 2008;87(5): 1212-1218.
22. Rattarasarn C, Leelawattana R, Soonthornpun S. Contribution of skeletal muscle mass on sex differences in 2-hour plasma glucose levels after oral glucose load in Thai subjects with normal glucose tolerance. *Metabolism.* 2010;59(2): 172-176.
23. von Doring ME, Jenssen T, Bollerslev J, et al. Visceral fat is better related to impaired glucose metabolism than body mass index after kidney transplantation. *Transpl Int.* 2015;28(10): 1162-1171.
24. Dedinska I, Laca L, Miklusica J, et al. Waist circumference as an independent risk factor for NODAT. *Ann Transplant.* 2015;20: 154-159.
25. Friedman J, Lussiez A, Sullivan J, Wang S, Englesbe M. Implications of Sarcopenia in Major Surgery. *Nutr Clin Pract.* 2015;30(2): 175-179.
26. Englesbe MJ, Lussiez AD, Friedman JF, Sullivan JA, Wang SC. Starting a Surgical Home. *Ann Surg.* 2015;262(6): 901-903.

Figure legends:

Figure 1. Morphomic measurements. Morphomic measurements are calculated from CT scans. The skin is outlined in green. The fascia is outlined in yellow. Within this fascial region, the visceral fat is portrayed by a density heat map. The psoas muscles are outlined by white dots. The vertical dashed line represents body depth (anterior-posterior axis), and the horizontal dashed line represents body width (lateral axis).

Figure 2. PTDM incidence by fat, muscle, and BMI. This graphs shows 1 year PTDM incidence by high/low muscle, fat, and BMI. The high group is designated as the upper gender-specific tertile of fat or muscle area, or BMI ≥ 30 . The low group is designated as the lower or middle gender-specific tertile of fat or muscle area, or BMI < 30 (*p < 0.05).

Author Manuscript

Table 1: Patient characteristics.

Demographic variables	
N	99
Male	64 (64.6%)
Age	52.9 ± 13.5
African American	25 (25.3%)
Body Mass Index	27.9 ± 6.4
ESRD etiology	
Hypertension	34 (34.3%)
Autoimmune	19 (19.2%)
Other etiology	54 (54.5%)
Hepatitis C positive	7 (7.1%)
Dialysis pre-transplant	74 (74.7%)
Dialysis vintage (years pre-transplant)	1.5 (0-4.2)
Prior kidney transplant	13 (13.1%)
Deceased donor	54 (54.5%)
Prednisone continued post-transplant	61 (61.6%)
Cyclosporine post-transplant	7 (7.1%)

Numbers represent N (%) or mean ± SD; dialysis vintage is represented as median (interquartile range).

Table 2. Factors associated with Post-transplant diabetes mellitus.

	OR	95% C.I.	p-value
Clinical variables			
Male	0.63	(0.22-1.76)	0.375
Age	1.01	(0.97-1.05)	0.615
African American	3.01	(1.03-8.80)	0.044
Body mass index	1.05	(0.98-1.13)	0.188
ESRD etiology:			
Hypertension	2.97	(1.04-8.44)	0.041
Autoimmune	0.47	(0.10-2.25)	0.345
Other etiology	0.61	(0.22-1.70)	0.344
Dialysis pre-transplant	3.17	(0.68-14.91)	0.144
Dialysis vintage (years pre-transplant)	1.24	(1.00-1.54)	0.048
Hepatitis C positive	1.90	(0.34-10.68)	0.466
Prednisone post-transplant	1.79	(0.58-5.49)	0.311
Morphomic variables			
Visceral fat area	1.84	(1.10-3.09)	0.020
Subcutaneous fat area	1.56	(0.94-2.58)	0.086
Subcutaneous fat anterior thickness	1.61	(0.97-2.66)	0.065
Total body area	1.67	(1.00-2.77)	0.049
Total body circumference	1.60	(0.95-2.69)	0.075
Body depth	1.79	(1.04-3.09)	0.035
Body width	1.25	(0.76-2.08)	0.380
Total psoas area	1.51	(0.91-2.51)	0.113
Average psoas density	1.11	(0.65-1.89)	0.700

Clinical and morphomic variables underwent univariate logistic regression. Morphomic variables were standardized by gender and coded in standard deviation units. C.I. = confidence interval

Table 3. Morphomic measures by post-transplant diabetes mellitus status.


Morphomic Component	No PTDM	PTDM	p
Visceral fat (mm ²)	14799 ± 9103	19996 ± 9620	0.047
Subcutaneous fat (mm ²)	23500 ± 12640	29927 ± 17992	0.165
Total body area (mm ²)	71753 ± 20713	82247 ± 25905	0.122
Total body circumference (mm)	983 ± 143	1049 ± 174	0.149
Body depth (mm)	250 ± 40	272 ± 43	0.057
Body width (mm)	353 ± 53	363 ± 64	0.506
Total psoas area (mm ²)	2294 ± 751	2351 ± 566	0.721
Average psoas density (Hounsfield units)	43 ± 7	44 ± 10	0.703

Numbers represent mean ± SD for all measures.

Table 4. Multivariate logistic regression.


	Model 1			Model 2			Model 3		
	Odds Ratio	95% C.I.	p-value	Odds Ratio	95% C.I.	p-value	Odds Ratio	95% C.I.	p-value
Visceral fat area	1.91	(1.05-3.48)	0.035						
Total body area				1.76	(0.87-3.56)	0.115			
Body depth							1.84	(0.92-3.67)	0.086
Body mass index	1.02	(0.93-1.11)	0.692	0.99	(0.89-1.11)	0.921	1.00	(0.90-1.10)	0.973
Hypertension	2.37	(0.72-7.83)	0.156	3.17	(1.00-10.13)	0.051	3.10	(0.97-9.89)	0.055
African American	3.23	(0.82-12.63)	0.092	2.26	(0.65-7.94)	0.202	2.17	(0.62-7.53)	0.224
Dialysis vintage (years pre-transplant)	1.14	(0.90-1.45)	0.287	1.15	(0.90-1.46)	0.261	1.16	(0.91-1.47)	0.235

Clinical and morphomic variables underwent multivariate logistic regression. A separate multivariate model was ran for each of visceral fat area, total body area, and body depth. Morphomic variables were standardized by gender and coded in standard deviation units. C.I. = confidence interval



ctr_13040_f1.tif

Author N



ctr_13040_f2.tif

Author Manuscript